A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19) (COVIDothèque)
Status
Conditions
Treatments
Details and patient eligibility
About
SARV-CoV-2 infection was considered pandemic on March 11, 2020. The SARV-CoV-2 epidemic affected France from the beginning of March, spreading in particular from a 4-day large evangelical meeting of 2500 people on February 17 in the city of Mulhouse (North East of France). The Montpellier University Hospital has set up a clinical pathway for people suspected of being infected with SARV-CoV-2 because of signs compatible with pneumonia (screening criteria in France during the study period). This includes an emergency department, an infectious disease department dedicated to the surveillance of infected people requiring hospital treatment, and an intensive care unit for the most severe cases. The diagnosis of infection with SARV-CoV-2 was confirmed in approximately 20% of people initially referred in this special care system.
The main objective of this cohorte is the collection of clinical data and biological samples from care for non-interventional research on the patients with a possible or confirmed SARS-CoV -2 infection, from diagnosis to long-term follow-up.
Enrollment
Sex
Volunteers
Inclusion criteria
- Patients care at the Montpellier University Hospital suspected of a COVID-19 infection
Exclusion criteria
- Patient opposed to the use of his data for research purposes
- Patient deprived of liberty by judicial decision
- Patient not affiliated to a social security scheme
Trial design
500 participants in 3 patient groups
Trial contacts and locations
Loading...
Central trial contact
Edouard TUAILLON, MD; PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal